Certain Meds Not Cost-Effective for First-Line Therapy of T2DM

Compared with metformin, SGLT2 inhibitors, GLP-1 receptor agonists cost more for treatment in drug-naive patients with type 2 diabetes

pills
Adobe Stock

MONDAY, Oct. 3, 2022 (HealthDay News) -- Sodium-glucose cotransporter-2 (SGTL2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists are effective as first-line therapy for patients with type 2 diabetes, but are not cost-effective, according to a study published online Oct. 4 in the Annals of Internal Medicine.

Jin G. Choi, from the University of Chicago, and colleagues examined the lifetime cost-effectiveness of a strategy of first-line SGLT2 inhibitors or GLP1 receptor agonists for drug-naive patients with type 2 diabetes.

The researchers found that the lifetime rates of congestive heart failure, ischemic heart disease, myocardial infarction, and stroke were lower with first-line SGLT2 inhibitors and GLP1 receptor agonists compared with metformin. Compared with first-line metformin, first-line SGLT2 inhibitors cost $43,000 more and added 1.8 quality-adjusted months ($478,000 per quality-adjusted life-year [QALY]). Compared with metformin, first-line injectable GLP1 receptor agonists cost more and reduced QALYs. In the sensitivity analysis, oral GLP1 receptor agonists were not cost-effective (incremental cost-effectiveness ratio, $823,000 per QALY). To be cost-effective at under $150,000 per QALY, costs would need to be under $5 and under $6 per day for SGLT2 inhibitors and oral GLP1 receptor agonists, respectively.

"In the interest of improving access to high-quality care in the United States, our study results indicate the need to reduce SGLT2 inhibitor and GLP1 receptor agonist medication costs substantially for patients with type 2 patients to improve health outcomes and prevent exacerbating diabetes health disparities," the authors write.

Abstract/Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on October 03, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ